Transactions
2
Insider / DuPont de Nemours, Inc.
CHANDY RUBY R
Director at DuPont de Nemours, Inc.
- Company
- DuPont de Nemours, Inc.
- First filing on record
- May 22, 2026
- Latest trade on record
- May 21, 2026
- SEC filings
- EDGAR ↗
CHANDY RUBY R, Director at DuPont de Nemours, Inc., has disclosed 2 transactions in DD, TMO since May 22, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed May 28, 2026, 7 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
4.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months CHANDY RUBY R reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 4,529 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| DD | Other A | May 21, 2026 | May 28, 2026 | 7d | 4,030 | — | — | late | Form 4 ↗ | |
| TMO | Other A | May 20, 2026 | May 22, 2026 | 2d | 499 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 28, 2026 | Form 4 | 0001628280-26-038879 | 1 | published | EDGAR ↗ |
| May 22, 2026 | Form 4 | 0000097745-26-000107 | 1 | published | EDGAR ↗ |
Other insiders at DuPont de Nemours, Inc.
- CASPER MARC N Chairman & CEO 163 rows
- Macpherson Donald G Chairman and CEO 40 rows
- McMaken Kurt B EVP, Chief Financial Officer 26 rows
- Pettiti Gianluca President & COO 24 rows
- Shafer Michael D Executive Vice President 23 rows
- Britt Lisa P. Sr. VP and Chief HR Officer 20 rows
- Lagarde Michel Director 19 rows
- BREEN EDWARD D Executive Chair 18 rows
- JOHNSON JENNIFER M Director 18 rows
- Lowery Frederick M. CEO 18 rows
Everyone on file, with contracts and lobbying under the company's name: DuPont de Nemours, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | May 22, 2026 | May 28, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.